Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy

Voichita Bar Ad, Gregory Weinstein, Pinaki R. Dutta, Ara Chalian, Stefan Both, Harry Quon

Research output: Contribution to journalArticle

Abstract

Background. This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors. Methods. Thirty cases of head and neck malignancies treated with radiotherapy were analyzed. Results. By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively. Likewise, during the last weeks of intensity-modulated radiation therapy (IMRT), only 35% of patients required additional narcotics for pain control, despite the presence of grade 2 or higher mucositis in 80% of cases. Conclusions. Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalHead and Neck
Volume32
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Mucositis
Neck
Radiotherapy
Head
Radiation
Pain
Narcotics
Neoplasms
Therapeutics
Drug and Narcotic Control
Controlled Clinical Trials
Retrospective Studies
gabapentin

Keywords

  • Gabapentin
  • Head and neck malignancies
  • IMRT
  • Radiation-induced mucositis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. / Bar Ad, Voichita; Weinstein, Gregory; Dutta, Pinaki R.; Chalian, Ara; Both, Stefan; Quon, Harry.

In: Head and Neck, Vol. 32, No. 2, 02.2010, p. 173-177.

Research output: Contribution to journalArticle

Bar Ad, Voichita ; Weinstein, Gregory ; Dutta, Pinaki R. ; Chalian, Ara ; Both, Stefan ; Quon, Harry. / Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. In: Head and Neck. 2010 ; Vol. 32, No. 2. pp. 173-177.
@article{a6eab68db25d4a278441151ee794ef87,
title = "Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy",
abstract = "Background. This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors. Methods. Thirty cases of head and neck malignancies treated with radiotherapy were analyzed. Results. By using a median dose of 2700 mg/day of gabapentin, only 10{\%} of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56{\%} and 73{\%} of the patients, respectively. Likewise, during the last weeks of intensity-modulated radiation therapy (IMRT), only 35{\%} of patients required additional narcotics for pain control, despite the presence of grade 2 or higher mucositis in 80{\%} of cases. Conclusions. Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials.",
keywords = "Gabapentin, Head and neck malignancies, IMRT, Radiation-induced mucositis",
author = "{Bar Ad}, Voichita and Gregory Weinstein and Dutta, {Pinaki R.} and Ara Chalian and Stefan Both and Harry Quon",
year = "2010",
month = "2",
doi = "10.1002/hed.21165",
language = "English (US)",
volume = "32",
pages = "173--177",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy

AU - Bar Ad, Voichita

AU - Weinstein, Gregory

AU - Dutta, Pinaki R.

AU - Chalian, Ara

AU - Both, Stefan

AU - Quon, Harry

PY - 2010/2

Y1 - 2010/2

N2 - Background. This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors. Methods. Thirty cases of head and neck malignancies treated with radiotherapy were analyzed. Results. By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively. Likewise, during the last weeks of intensity-modulated radiation therapy (IMRT), only 35% of patients required additional narcotics for pain control, despite the presence of grade 2 or higher mucositis in 80% of cases. Conclusions. Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials.

AB - Background. This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors. Methods. Thirty cases of head and neck malignancies treated with radiotherapy were analyzed. Results. By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively. Likewise, during the last weeks of intensity-modulated radiation therapy (IMRT), only 35% of patients required additional narcotics for pain control, despite the presence of grade 2 or higher mucositis in 80% of cases. Conclusions. Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials.

KW - Gabapentin

KW - Head and neck malignancies

KW - IMRT

KW - Radiation-induced mucositis

UR - http://www.scopus.com/inward/record.url?scp=74749092026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749092026&partnerID=8YFLogxK

U2 - 10.1002/hed.21165

DO - 10.1002/hed.21165

M3 - Article

C2 - 19572284

AN - SCOPUS:74749092026

VL - 32

SP - 173

EP - 177

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 2

ER -